Abbott Laboratories (ABT) · Jul 16, 2026 · Earnings

Adjusted EPS and revenue edged past estimates; full-year EPS outlook raised

Beat — adjusted EPS $1.31 vs ~$1.28 consensus

Adjusted EPS and revenue edged past estimates; full-year EPS outlook raised

The quarter modestly cleared the market bar. Adjusted diluted EPS was $1.31 versus a published consensus of roughly $1.28, while sales reached $12.593 billion versus approximately $12.48 billion expected.

Metric2Q26ComparisonRead-through
Net sales$12.593B$11.142B prior yearReported growth of 13.0%; comparable growth only 4.8% (Financial Highlights; Comparable Revenue table)
Adjusted diluted EPS$1.31$1.26 prior year; ~$1.28 consensus4.0% year-over-year growth and a modest beat (Financial Highlights)
GAAP diluted EPS$0.53$1.01 prior yearHeavily distorted by $1.362B of specified after-tax charges (Financial Highlights; Specified Items)
Medical Devices comparable sales——8.4% growth, led by electrophysiology and diabetes care (Sales — Medical Devices)
Diagnostics comparable sales——2.9% growth excluding the Exact Sciences acquisition (Sales — Diagnostics)
Nutrition comparable sales——Down 3.6% (Sales — Nutrition)

The headline sales growth overstates the underlying acceleration. The 13.0% reported increase includes the Exact Sciences acquisition and foreign-exchange effects; comparable sales grew 4.8%. Medical Devices remained the cleanest operating engine at 8.4% comparable growth, but Nutrition declined 3.6% and Diagnostics grew only 2.9% excluding acquired Exact Sciences revenue (Comparable Revenue table; Sales — Medical Devices; Sales — Nutrition; Sales — Diagnostics).

Earnings quality was better than GAAP, but cost pressure remains visible. Adjusted EPS rose 4.0%, yet total operating costs increased 19.9% against 13.0% reported sales growth. The gap reflects higher amortization, acquisition-related costs, legal reserves and other specified items; excluding those charges, earnings improved, but the filing does not show broad operating leverage (Income Statement; Specified Items).

Management raised the full-year earnings range, making the net read better than the small quarterly beat alone. Full-year adjusted EPS guidance increased to $5.45–$5.60 from $5.38–$5.58, while comparable sales growth guidance was reaffirmed at 6.5%–7.5%. That is a modest upgrade rather than a major reset: the earnings range moved higher, but the sales outlook did not, leaving the result narrowly ahead of expectations rather than a broad fundamental reacceleration.

What to watch next

Q3 earnings report, mid-October 2026

Original filing on SEC EDGAR

More Abbott Laboratories news

Adjusted EPS and revenue edged past estimates; full-year EPS outlook raised | ABT Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.